PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项为期五年的研究，旨在评估聚乙二醇化干扰素联合或不联合利巴韦林治疗6-18岁儿童丙型肝炎的效果。副作用、对生长、体重和心理特征的影响以及生活方式的变化也通过辅助研究进行监测。这项研究由美国国立卫生研究院资助，部分由罗氏制药公司资助。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a five year study to assess the effect of treatment of Hepatitis C with pegylated interferon with or without ribavirin in children between ages 6-18. The side effects , effects on growth, weight and psychological profile and life style changes are also monitored through ancillary studies. The study is funded by the NIH and in part by Roche Pharmacueticals.